We are studying the effects of AMG 193, alone and with other treatments, in patients with advanced thoracic tumors that have a specific genetic deletion. This research aims to find better treatment options for these patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-small cell lung cancer (NSCLC) is a type of lung cancer that includes several subtypes and is characterized by uncontrolled cell growth in the lungs. It is the most common form of lung cancer and can lead to symptoms such as persistent cough, chest pain, and difficulty breathing.
Thoracic tumors with homozygous MTAP-deletion refer to a specific type of tumor located in the chest area that has a genetic alteration involving the MTAP gene. This condition may have implications for treatment options and clinical trials.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
